← Back to home

ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) AT HIGH RISK OF RECURRENCE AFTER CURATIVE RESECTION OR ABLATION

Clinical trials for ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) AT HIGH RISK OF RECURRENCE AFTER CURATIVE RESECTION OR ABLATION explained in plain language.

Never miss a new study

Get alerted when new ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) AT HIGH RISK OF RECURRENCE AFTER CURATIVE RESECTION OR ABLATION trials appear

Sign up with your email to follow new studies for ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) AT HIGH RISK OF RECURRENCE AFTER CURATIVE RESECTION OR ABLATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Drug duo vs. solo: battle to keep liver cancer at bay after surgery

Disease control Completed

This study tested whether adding a second drug (rivoceranib) to a standard immunotherapy (camrelizumab) is better at preventing liver cancer from returning after initial surgery or ablation. It involved 251 patients who were at high risk of their cancer coming back. The goal was …

Matched conditions: ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) AT HIGH RISK OF RECURRENCE AFTER CURATIVE RESECTION OR ABLATION

Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control

Last updated Apr 02, 2026 07:42 UTC

ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) AT HIGH RISK OF RECURRENCE AFTER CURATIVE RESECTION OR ABLATION

Get alerted when new ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) AT HIGH RISK OF RECURRENCE AFTER CURATIVE RESECTION OR ABLATION trials appear

Drug duo vs. solo: battle to keep liver cancer at bay after surgery